Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 04 Dec 2019
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 05 Dec 2019
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

Role of genomics in colorectal cancers

Dr Joslyn Ngu
04 Dec 2017

Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.

Colorectal cancer is not a single disease, but a set of molecularly distinctive diseases with the same clinical presentation, said Associate Professor Ho Gwo Fuang, clinical oncologist at the University Malaya Medical Centre. By stratifying patients into clinically relevant molecular subtypes, treatment can be more personalized. Genomics advancements has allowed for better risk stratification of early stage disease and these are carried out by gene signature profiling tools such as ColoPrint, Ocotype Dx and ColDx (now called GeneFx Colon).

There are four consensus molecular subtypes of CRCs: CSM1 to 4. CSM1 tumours are more commonly found in the proximal colon. Generally, they are poorly differentiated, of mucinous subtype and have dense lymphocytic infiltration. This indicates strong antitumoural immune response which makes good targets for immune checkpoint inhibitors. CSM 2 to 4 are usually located towards the distal part of the colon and rectum. CSM 2 and 3 tumours are immune-ignorant and CSM 4 tumours are immune-tolerant. The most common mutation pathways in CRC include APC, RAS and Wnt pathways. The last occurs in 93 percent of patients, he said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 04 Dec 2019
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 05 Dec 2019
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).